The verdict
Our read at a glance.
Whether mazdutide's dual GLP-1/glucagon agonism delivers durable weight and metabolic benefits with acceptable safety, and how to weigh its China approval against its still-developing global evidence and regulatory status.
- The signal
- Phase 2 and phase 3 trials, largely in China, show mazdutide produces significant weight loss versus placebo and improves blood sugar, which led to its 2025 approval in China for weight management. Liver-fat and metabolic effects are being studied.
- The unknown
- Its long-term safety and durability, head-to-head standing against tirzepatide and other incretins, whether the glucagon component's energy-expenditure and liver benefits hold up, and whether it gains approval beyond China.
- Our read
- A promising next-generation obesity drug: a GLP-1/glucagon dual agonist that clearly drives weight loss and won approval in China in 2025, but whose long-term safety, durability, and standing against the leading incretins are still being worked out, and which is not yet approved outside China. Read it as regionally approved and rapidly maturing, not a finished, globally-established therapy.
The mechanism
How it works.
Gut hormones released after eating tell the body to feel full and to handle sugar and fat; the natural hormone oxyntomodulin happens to switch on two of these receptors at once, GLP-1 and glucagon. Mazdutide is a lab-made, long-acting copy of that dual-action design. Through the GLP-1 receptor it curbs appetite, slows stomach emptying, and improves insulin release (the same way drugs like semaglutide work); through the glucagon receptor it is thought to raise energy expenditure and help clear fat from the liver. Combining both is meant to add to the weight and metabolic benefits of GLP-1 alone, and a fatty-acid tail lets it last about a week per injection.
Safety & regulatory boundary
The consequential part.
Like other incretin drugs, mazdutide commonly causes nausea, vomiting, and diarrhea, especially early; the added glucagon activity raises questions about heart rate and blood-sugar effects that ongoing trials are tracking. It is approved in China for weight management but is investigational and not FDA-approved in the US or most other regions, so it should not be treated as broadly available or fully established. It is a prescription drug, not a supplement or research-chemical product.
What's next
What we're watching.
Global regulatory decisions, long-term outcome and safety data, liver (MASH) results, and head-to-head comparisons with tirzepatide and other dual and triple agonists.
Context
Why this is discussed.
Mazdutide is part of the next wave of obesity drugs that hit more than one target. By switching on the glucagon receptor in addition to GLP-1, it aims to add energy-burning and liver-fat benefits on top of the appetite suppression that GLP-1 drugs already provide. It is one of the dual agonists (alongside survodutide) following tirzepatide and retatrutide.
The evidence base
10 cited references.
Registered trials5
ClinicalTrials.gov · PHASE3 · COMPLETED · 2024-02-29
ClinicalTrials.gov · PHASE3 · RECRUITING · 2026-04-23
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2025-05-09
ClinicalTrials.gov · PHASE2 · COMPLETED · 2023-11-17
ClinicalTrials.gov · NA · RECRUITING · 2026-04
Indexed literature (PubMed)5
Ji L et al. · N Engl J Med · 2025
Xie Z et al. · Metabolism · 2024
Ji L et al. · EClinicalMedicine · 2022
Ji L et al. · Nat Commun · 2023
Zhang B et al. · Diabetes Care · 2024
Keep reading